In the latest podcast episode, Optimum Strategic Communications’ Eva Haas gives her thoughts on the trends in the biopharma market for 2023. After the geopolitical upheavals of last year, according to some sources there has been a gradual recovery. For instance an analysis by Clarivate and the BioIndustry Association trade body secured £382 million in […]
• Etienne Fradet brings extensive industry expertise and a successful track record in bringing innovative microfluidic technologies to market • Appointment strengthens Astraveus’ position in the CGT manufacturing field as it looks to develop and commercialise its Lakhesys platform Paris, France, 31 August, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, […]
OSLO, Norway, August 31 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its first half and second quarter 2023 results. Chief Executive Officer of Lytix Biopharma, Dr. Øystein Rekdal, commented: “We have continued to make positive progress as we build a clinical Phase II […]
Alchemab is a Cambridge biotech that aims to revolutionise drug discovery with a novel alternative to big pharma’s classic “choose a target” approach. Optimum’s Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more. The UK has long been a leader in the field of antibody drug technology, and it was British […]
There’s an increasing focus on using drugs to modify the tumour microenvironment, reducing immunosuppression and breaking down the barrier of fibrotic scar tissue that blocks many therapies. Optimum Strategic Communications’ Richard Staines talked to our client iOnctura, about the Company’s plans to use an autotaxin inhibitor to remove this obstacle. Scientists are looking at a […]
